Top > Search of International Patents > ANTI-HEPATOMA-VIRUS AGENT

ANTI-HEPATOMA-VIRUS AGENT UPDATE_EN

Foreign code F170009243
File No. (S2016-0463-N0)
Posted date Sep 21, 2017
Country WIPO
International application number 2017JP009674
International publication number WO 2017155082
Date of international filing Mar 10, 2017
Date of international publication Sep 14, 2017
Priority data
  • P2016-048664 (Mar 11, 2016) JP
Title ANTI-HEPATOMA-VIRUS AGENT UPDATE_EN
Abstract The purpose of the present invention is to provide a novel therapeutic agent against hepatoma viruses. Specifically, the present invention pertains to an anti-hepatoma-virus agent containing, as an active ingredient, a compound represented by general formula (I): (in the formula, R1 is fluorine or hydrogen) or a pharmacologically acceptable salt thereof.
Scope of claims [claim1]
1. General formula (i) below:
[Conversion 1]
(In formula, R [1] is fluorine or hydrogen)
So the chemical compound which is shown or it contains the salt which that pharmacy is allowed, as the active ingredient the anti- liver tumor virus medicine.
[claim2]
2. The chemical compound which is shown with general formula (i) or the salt which that pharmacy is allowed 2 - kuroro - 9- (2 - deoxy - 2 - fluoro - .beta.-D-arabinohuranoshiru) adenine or is the salt which that pharmacy is allowed, at the same time the liver tumor virus the B type hepatitis virus and/or is C type hepatitis virus, the anti- liver tumor virus medicine of claim 1 statement.
[claim3]
3. The chemical compound which is shown with general formula (i) or the salt which that pharmacy is allowed 2 - kuroro - 9- (2 - deoxy - 2 - fluoro - .beta.-D-arabinohuranoshiru) adenine or is the salt which that pharmacy is allowed, at the same time the liver tumor virus is the B type hepatitis virus or C type hepatitis virus, the anti- liver tumor virus medicine of claim 1 statement.
[claim4]
4. The chemical compound which is shown with general formula (i) or the salt which that pharmacy is allowed 2 - kuroro - 9- (2 - deoxy - 2 - fluoro - .beta.-D-arabinohuranoshiru) adenine or is the salt which that pharmacy is allowed, at the same time the liver tumor virus is the B type hepatitis virus, the anti- liver tumor virus medicine of claim 1 statement.
[claim5]
5. The chemical compound which is shown with general formula (i) or the salt which that pharmacy is allowed 2 - kuroro - 9- (2 - deoxy - 2 - fluoro - .beta.-D-arabinohuranoshiru) adenine or is the salt which that pharmacy is allowed, at the same time the liver tumor virus is C type hepatitis virus, the anti- liver tumor virus medicine of claim 1 statement.
[claim6]
6. The chemical compound which is shown with general formula (i) or the salt which that pharmacy is allowed 2 - kuroro - 9- (2 - deoxy - .beta.-D-arabinohuranoshiru) adenine or is the salt which that pharmacy is allowed, at the same time the liver tumor virus is C type hepatitis virus, the anti- liver tumor virus medicine of claim 1 statement.
[claim7]
7. Being liver tumor virus-related diseased prevention or the remedy medicine which contains the anti- liver tumor virus medicine of claim 1 statement, the aforementioned-related disease the chronic hepatitis, is selected from the group which consists of the hepatic cirrhosis and the liver cancer, the aforementioned prevention or the remedy medicine.
[claim8]
8. 2 - kuroro - 9- (2 - deoxy - 2 - fluoro - .beta.-D-arabinohuranoshiru) adenine or the anti- liver tumor virus medicine which is the salt which that pharmacy is allowed is contained, at the same time the liver tumor virus-related disease the B type hepatitis virus and/or is C type hepatitis virus-related disease, the preventive of claim 7 statement or remedy medicine.
[claim9]
9. 2 - kuroro - 9- (2 - deoxy - 2 - fluoro - .beta.-D-arabinohuranoshiru) adenine or the anti- liver tumor virus medicine which is the salt which that pharmacy is allowed is contained, at the same time the liver tumor virus-related disease is the B type hepatitis virus or C type hepatitis virus-related disease, the preventive of claim 7 statement or remedy medicine.
[claim10]
10. 2 - kuroro - 9- (2 - deoxy - 2 - fluoro - .beta.-D-arabinohuranoshiru) adenine or the anti- liver tumor virus medicine which is the salt which that pharmacy is allowed is contained, at the same time the liver tumor virus-related disease is the B type hepatitis virus-related disease, the preventive of claim 7 statement or remedy medicine.
[claim11]
11. 2 - kuroro - 9- (2 - deoxy - 2 - fluoro - .beta.-D-arabinohuranoshiru) adenine or the anti- liver tumor virus medicine which is the salt which that pharmacy is allowed is contained, at the same time the liver tumor virus-related disease is C type hepatitis virus-related disease, the preventive of claim 7 statement or remedy medicine.
[claim12]
12. 2 - kuroro - 9- (2 - deoxy - .beta.-D-arabinohuranoshiru) adenine or the anti- liver tumor virus medicine which is the salt which that pharmacy is allowed is contained, at the same time the liver tumor virus-related disease is C type hepatitis virus-related disease, the preventive of claim 7 statement or remedy medicine.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • KAGOSHIMA UNIVERSITY
  • OKAYAMA UNIVERSITY
  • DAIKIN INDUSTRIES, LTD.
  • Inventor
  • IKEDA MASANORI
  • TAKEDA MIDORI
  • BABA MASANORI
  • KATO NOBUYUKI
IPC(International Patent Classification)
Specified countries (WO2017155082)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close